Emerald Advisers’s Pacira BioSciences PCRX Stock Holding History

Emerald Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-224,625	Closed	-$8.67M	–	243
2022 Q4	$8.67M	Sell	224,625 -269,671	-55%	-$13.1M	0.42%	93
2022 Q3	$26.3M	Buy	494,296 +155,076	+46%	+$8.62M	1.36%	17
2022 Q2	$19.8M	Buy	339,220 +34,172	+11%	+$2.24M	1.02%	32
2022 Q1	$23.3M	Buy	+305,048	New	+$20.3M	0.89%	42

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Emerald Advisers's PCRX Position: Q1 2023 in Review

Emerald Advisers sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 224,625 shares — an estimated $8.67M sold.

Emerald Advisers first reported a position in PCRX in Q1 2022 and held it in 4 quarters. The position peaked at $26.3M in Q3 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Emerald Advisers reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Emerald Advisers sold 224,625 Pacira BioSciences shares in Q1 2023, an estimated $8.67M.
Emerald Advisers first reported a position in Pacira BioSciences in Q1 2022 and held it in 4 quarters.
Emerald Advisers's Pacira BioSciences position peaked at $26.3M in Q3 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Emerald Advisers's 13F filing for Q1 2023, filed 4 May 2023.